Perspective Therapeutics logo
Perspective Therapeutics
CATX | AMEX
Chart Builder DCF Calculator
$0.94
$0.00 (-0.33%)
At close: Nov 16, 2026, 3:59 PM ET
$0.96
+$0.02 (+1.79%)
After-hours: Nov 16, 2026, 7:18 PM ET

Perspective Therapeutics Company Profile

Company profile explained

Company Profile

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

Key Executives

Name Position
Johan Spoor Chief Executive Officer & Director
Andrew Bright Executive Vice President of Brachytherapy
Annie J. Cheng Vice President of Investor Relations
Chris Nenno General Counsel & Corporate Secretary
Joel David Sendek CFO & Principal Financial Officer
Jonathan R. Hunt Chief Accounting Officer
Markus Puhlmann Chief Medical Officer
Michael K. Schultz Co-Founder & Senior Scientific Advisor
Paul Lyne Chief Science Officer
Shane Cobb Executive Vice President of Operations

Latest SEC Filings

Date Type Title
Oct 23, 2026 8-K Current Report
Oct 08, 2026 8-K Current Report
Oct 01, 2026 8-K Current Report
Sep 23, 2026 SC 13D/A [Amend] Filing
Sep 14, 2026 8-K Current Report
Sep 08, 2026 8-K Current Report
Sep 08, 2026 4 Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 SC 13D/A [Amend] Filing
View All SEC Filings ➞
Perspective Therapeutics
Perspective Therapeutics logo
Country United States
IPO Date Nov 10, 2005
Industry Medical - Devices
Sector Healthcare
Employees 165
CEO Johan Spoor

Contact Details

2401 Elliott Avenue Seattle, Washington 98121 United States

Stock Details

Ticker Symbol CATX
Exchange AMEX
Fiscal Year July - June
Reporting Currency USD
CIK Code 0000728387
CUSIP Number 46489V302
ISIN Number US46489V3024
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.